LWAY
Not a bad business — just a pricey one
Lifeway Foods is doing the thing every company dreams about: growing revenue, boosting profitability, and selling more branded kefir. The business itself sounds pretty healthy. The stock, though? That’s where the story gets spicy.
When the multiple starts acting up
The article argues that LWAY has already sprinted past the S&P 500, but the valuation has kept climbing like it’s trying to win a prize. Even with facility upgrades and expansion plans in the mix, the shares apparently trade at the richest multiples in the peer group — and not just on next quarter’s numbers, but even on 2027 forward estimates.
The investor takeaway
That’s why the call lands as a soft sell. It’s not a thesis that Lifeway is broken; it’s a thesis that expectations may have gotten a little too caffeinated. If the company keeps executing, the business can still look good. But if the stock is already priced like perfection, the upside gets a lot harder to justify.
Big picture: this is the market’s favorite plot twist — the company is fine, the stock just got ahead of the story.